Sponsors
The bill aims to expand access to and clarity around Medicare reimbursement for AI-enabled remote monitoring—benefiting patients and providers—but risks higher Medicare spending and administrative strain, and could still lead to coverage problems if guidance is unclear.
Patients with chronic conditions (especially Medicare beneficiaries) gain greater access to advanced remote monitoring (e.g., continuous glucose monitors with adaptive AI) because clearer reimbursement pathways make these devices more likely to be covered.
Medicare beneficiaries face less billing uncertainty for AI-enabled remote monitoring devices and services because the bill requires clearer payment rules, reducing the risk of unexpected denials or confusing claims.
Clinicians and health systems get clearer guidance on which remote monitoring services and devices are reimbursable, which should encourage adoption and simplify clinical and administrative workflows.
Taxpayers and the Medicare program could face higher spending if the guidance leads to more AI-enabled devices and remote monitoring services becoming reimbursable.
If HHS issues vague or overly restrictive guidance, Medicare beneficiaries (including those with chronic conditions) may experience coverage delays or denials for AI-enabled monitoring devices.
The requirement to issue technical guidance quickly (by 2027) may strain HHS resources, producing incomplete or frequently revised guidance that burdens federal staff and healthcare providers.
Based on analysis of 2 sections of legislative text.
Directs HHS to issue guidance by Jan 1, 2027 clarifying Medicare Part B payment rules for AI-enabled remote monitoring devices that transmit data to providers.
Introduced January 3, 2025 by David Schweikert · Last progress January 3, 2025
Directs the Department of Health and Human Services to issue guidance by January 1, 2027 clarifying how Medicare Part B pays for remote monitoring devices that include an artificial intelligence component and transmit data to health care providers for treatment and management. The guidance must be distributed using existing HHS communication channels and focuses on payment requirements for devices such as continuous glucose monitors with AI-driven features.